Avinger, Inc.

63 articles with Avinger, Inc.

• Avinger Reports Fourth Quarter 2022 Results

  3/15/2023

  Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the fourth quarter and full year ended December 31, 2022.

• Avinger to Announce Fourth Quarter 2022 Results on March 15

  3/2/2023

  Avinger, Inc. today announced that it will release its financial results for the fourth quarter and full year 2022 after the close of trading on Wednesday, March 15, 2023.

• Avinger Announces 510(k) Filing of Pantheris LV

  1/11/2023

  Avinger, Inc. today announced the Company submitted a new 510(k) application to the U.S. Food & Drug Administration for Pantheris LV.

• Avinger to Announce Third Quarter 2022 Results on November 9

  11/1/2022

  Avinger, Inc. today announced that it will release its financial results for the third quarter 2022 after the close of trading on Wednesday, November 9, 2022.

• Avinger to Present at LD Micro Investor Conference

  10/19/2022

  Avinger, Inc. today announced that Chief Executive Officer Jeff Soinski will participate in the following investor conference event during October 2022.

• Interim Data from IMAGE-BTK Clinical Trial Presented at AMP 2022

  9/1/2022

  Avinger, Inc. announced the presentation of interim data from the IMAGE-BTK clinical study for Pantheris SV at the annual AMP conference in August.

• Avinger Reports Second Quarter 2022 Results

  8/11/2022

  Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the second quarter ended June 30, 2022.

• Avinger, Inc. Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-the-Market Under Nasdaq Rules

  8/8/2022

  Avinger, Inc. announced the closing of its previously announced registered direct and private placement offerings priced at-the-market under Nasdaq rules, including the issuance and sale of 700,000 shares of common stock and 784,019 pre-funded warrants in the registered direct offering and 1,369,864 pre-funded warrants in the private placement.

• Avinger to Announce Second Quarter 2022 Results on August 11

  8/5/2022

  Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced that it will release its financial results for the second quarter 2022 after the close of trading on Thursday, August 11, 2022.

• Avinger Announces $5 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

  8/4/2022

  Avinger, Inc. today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the sale and issuance of 1,484,019 shares of the Company's common stock.

• Avinger Announces Filing of 510(k) Submission for Tigereye ST Image-Guided CTO Crossing System

  7/6/2022

  Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for the Tigereye ST catheter.

• Avinger Expands International Presence with First Commercial Shipment to Chile

  6/21/2022

  Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the expansion of its international presence with the commercial launch of its Lumivascular products in Chile.

• Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC 2022

  6/15/2022

  Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations and a live case transmission featuring the company's Lumivascular technology at the Leipzig Interventional Course (LINC) 2022.

• Avinger Announces Key Opinion Leader Presentation and Live Case at Vascular Conferences in Germany

  5/16/2022

  Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced a key opinion leader (KOL) presentation and a live-case event featuring the Company's Lumivascular technology at two important vascular conferences in Germany.

• Avinger Reports First Quarter 2022 Results

  5/10/2022

  Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2022.

• Avinger to Announce First Quarter 2022 Results on May 10

  4/29/2022

  Avinger, Inc., announced that it will release its financial results for the first quarter 2022 after the close of trading on Tuesday, May 10, 2022.

• Avinger Announces Full Commercial Launch of Lightbox 3

  4/19/2022

  Avinger, Inc. today announced full commercial availability of its new Lightbox 3 imaging console designed to enhance the user experience and drive faster adoption at new hospital sites.

• Avinger Announces Issuance of Three New U.S. Patents in March 2022

  3/30/2022

  Avinger, Inc. today announced the issuance of three new U.S. patents in March 2022 and provided an update on the expansion of its intellectual property portfolio.

• Avinger Regains Compliance with Nasdaq Listing Requirements - Mar 29, 2022

  3/29/2022

  Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced it has regained compliance with Nasdaq listing requirements.

• Avinger Reports Fourth Quarter and Year End 2021 Results

  3/22/2022

  Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the fourth quarter and full year ended December 31, 2021.